F5 and hyperinsulinemic hypoglycemia, familial, 4: This pharmaco-economic reality is, however, not compatible with the need for an effective treatment for patients suffering from FV deficiency, who are still awaiting the commencement of the first clinical trials of a recombinant FV that has been demonstrated to be highly effective for this condition.